1 The effect of D-cycloserine on brain processing of breathlessness over

2 pulmonary rehabilitation - an experimental medicine study

3

- Sarah L. Finnegan¹ (sarah.finnegan@ndcn.ox.ac.uk) 5
- Olivia K. Harrison ^{1,2,3} 6
- 7 Sara Booth ¹⁰
- 8 Andrea Dennis¹²
- 9 Martyn Ezra¹
- 10 Catherine J. Harmer ^{4,5}
- Mari Heriqstad⁶ 11
- Bryan Guillaume⁸ 12
- Thomas E. Nichols 8,1 13
- Najib M. Rahman 7,9 14
- Andrea Reinecke⁴ 15
- Olivier Renaud ¹¹ 16
- 17 Kyle T.S. Pattinson¹ (kyle.pattinson@nda.ox.ac.uk)
- 18
- 19 ¹. Wellcome Centre for Integrative Neuroimaging and Nuffield Division of Anaesthetics,
- 20 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
- 21 ². Translational Neuromodeling Unit, Institute for Biomedical Engineering, University of
- 22 Zurich and ETH Zurich, Switzerland.
- 23 ³. School of Pharmacy, University of Otago, Dunedin, New Zealand
- 24 ⁴. Department of Psychiatry, Medical Sciences, University of Oxford, Oxford, UK;
- 25 ⁵. Oxford Health NHS Foundation Trust, Warneford Hospital Oxford
- 26 ⁶. Department of Biosciences and Chemistry, Sheffield Hallam University, Sheffield,
- 27 UK
- 28 NOTE: Wis frightin Deptartemente of Wieding me bearing this its of Oxford, Oxford,

- ⁸. Oxford Big Data Institute, Li Ka Shing Centre for Health Information and
- 30 Discovery, Nuffield Department of Population Health, University of Oxford, Oxford
- 31 OX3 7LF UK
- 32 ⁹. Oxford NIHR Biomedical Research Centre, Oxford OX3 7JX
- ¹⁰. Cambridge Breathlessness Intervention Service, Box 63, Elsworth House,
- 34 CUNHSFT, Hills Road, Cambridge CB2 200
- 35 ¹¹. Department of Psychology, University of Geneva, Switzerland
- 36 ¹². Perspectum, Oxford, OX4 2LL
- 37
- 38 Corresponding author: Sarah L. Finnegan; <u>sarah.finnegan@ndcn.ox.ac.uk</u>
- 39 6th Floor, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU; 01865 234 544
- 40
- 41 Author contributions
- 42 **S.L.F** Acquisition of data, analysis, interpretation, drafting, editing and approving
- 43 manuscript
- 44 **O.K.H I**nterpretation, editing and approving manuscript
- 45 **S.B** Study design, editing and approving manuscript
- 46 **A.D** Acquisition of data, analysis, approving manuscript
- 47 **M.E** Analysis, editing and approving manuscript
- 48 **B.G** Analysis, approving manuscript
- 49 **C.J.H** Study design, editing and approving manuscript
- 50 **M.H** Study design, acquisition of data, editing and approving manuscript
- 51 **T.N** Analysis, approving manuscript
- 52 N.M.R Study design, editing and approving manuscript
- 53 **O.R** Analysis, approving manuscript
- 54 **A.R -** Study design, editing and approving manuscript
- 55 **K.T.S.P** Study design, interpretation, editing and approving manuscript

57 Funding

58 This work was supported by the Dunhill Medical Trust (Grant R333/0214) and the 59 National Institute for Health Research Biomedical Research Centre (Grant 60 RCF18/002) based at Oxford University Hospitals NHS Foundation Trust and The 61 University of Oxford. This research was funded in whole, or in part, by the Wellcome 62 Trust 203139/Z/16/Z. For the purpose of Open Access, the author has applied a CC 63 BY public copyright licence to any Author Accepted Manuscript version arising from 64 this submission. OKH was supported via funding from the European Union's Horizon 65 2020 research and innovation programme under the Grant Agreement No 793580, and 66 as a Rutherford Discovery Postdoctoral Fellow from the Royal Society of New Zealand. 67 CJH is supported by the National Institute for Health Research Biomedical Research 68 Centre based at Oxford Health NHS Foundation Trust and The University of Oxford, 69 and by the UK Medical Research Council. KTSP and NMR are supported by the 70 National Institute for Health Research Biomedical Research Centre based at Oxford 71 University Hospitals NHS Foundation Trust and the University of Oxford. AR is funded 72 by a fellowship from MQ. Transforming mental health.

73

74 Disclosures

75 Dr. Harmer has valueless shares in p1vital and serves on their advisory panel. She 76 has received consultancy payments from p1vital, Zogenix, J&J, Pfizer, Servier, Eli-77 Lilly, Astra Zeneca, Lundbeck. Dr. Pattinson and Dr Ezra are named as co-inventors 78 on a provisional U.K. patent application titled "Use of cerebral nitric oxide donors in the 79 assessment of the extent of brain dysfunction following injury. Dr. Rahman, has 80 received consulting fees from Rocket Medical U.K. Prof. Nichols has received consulting fees from Perspectum Diagnostics. The remaining authors have no 81 82 biomedical financial interests or potential conflicts of interest.

- 83
- 84

0	5
0	J

86 Abstract

87 Background: Pulmonary rehabilitation is the best treatment for chronic 88 breathlessness in COPD but there remains an unmet need to improve efficacy. Pulmonary rehabilitation has strong parallels with exposure-based cognitive 89 90 behavioural therapies (CBT), both clinically and in terms of brain activity patterns. The 91 partial NMDA-receptor agonist, D-cycloserine has shown promising results in 92 enhancing efficacy of CBT, thus we hypothesised that it would similarly augment the 93 effects of pulmonary rehabilitation in the brain. Positive findings would support further 94 development in phase 3 clinical trials.

95 Methods: 72 participants with mild-to-moderate COPD were recruited to a double-96 blind pre-registered (ID: NCT01985750) experimental medicine study running parallel 97 to a pulmonary rehabilitation course. Participants were randomised to 250mg D-98 cycloserine or placebo, administered immediately prior to the first four sessions of 99 pulmonary rehabilitation. Primary outcome measures were differences between D-100 cycloserine and placebo in brain activity in the anterior insula, posterior insula, anterior 101 cingulate cortices, amygdala and hippocampus following completion of pulmonary 102 rehabilitation. Secondary outcomes included the same measures at an intermediate 103 time point and voxel-wise difference across wider brain regions.

104 Results: No difference between D-cycloserine and placebo groups was observed 105 across the primary or secondary outcome measures. Questionnaire and measures of 106 respiratory function showed no group difference.

107 **Conclusions:** This is the first study testing brain-active drugs in pulmonary 108 rehabilitation. Rigorous trial methodology and validated surrogate end-points 109 maximised statistical power. Although increasing evidence supports therapeutic 110 modulation of NMDA pathways to treat symptoms, we conclude that a phase 3 clinical 111 trial of D-cycloserine would not be worthwhile.

112

- 113
- 114 Key Words: Neuroimaging, breathlessness-expectation, brain-active drugs, cognitive
- 115 behavioural therapy
- 116
- 117 Key Messages:

118 What is the key question?

- 119 Does the partial NMDA-receptor agonist, D-cycloserine, augment the effects of
- 120 pulmonary rehabilitation on breathlessness related brain activity?

121 What is the bottom line?

- 122 Rigorous trial methodology and validated surrogate end-points revealed no effect of
- 123 D-cycloserine on breathlessness related brain activity across pulmonary rehabilitation.

124 Why read on?

- 125 This study highlights both the value of functional magnetic resonance imaging in "de-
- 126 risking" expensive clinical trials and provides detailed investigation of brain-targeted
- 127 points for pharmacological treatments of breathlessness.

128 Introduction

129 130 Chronic breathlessness is a central symptom of chronic obstructive pulmonary disease 131 (COPD). Currently, pulmonary rehabilitation offers the most effective treatment 132 strategy for chronic breathlessness in COPD. However, around 30% of patients derive 133 no clinical benefit [1]. Health-related benefits plateau within the first 6-months following 134 pulmonary rehabilitation, returning to pre-rehabilitation levels for the majority of 135 patients after 12-18 months [2]. Thus, there remains an unmet need to develop 136 strategies to increase or prolong the beneficial effects of pulmonary rehabilitation.

137

138 A body of evidence has shown that improvements in breathlessness over pulmonary 139 rehabilitation result from a reappraisal of the sensory experience [3, 4], arresting the 140 downward spiral of fear, avoidance and physical deconditioning. The safe, graded 141 exposure to breathlessness within pulmonary rehabilitation parallels techniques of 142 exposure-based cognitive behavioural therapy (CBT), in which pathological fears are 143 first activated and then disconfirmed by new adaptive information. These similarities 144 are highted by clinical studies of both pulmonary rehabilitation and cognitive 145 behavioural therapy, which show changes to brain activity within areas associated with 146 attention and learned sensory and emotional expectations such as cingulate cortex. 147 angular gyrus, insula and supramarginal gyrus, [4, 5].

148

149 In the field of psychiatry, there has been great interest in the partial NMDA agonist D-150 cycloserine, as a pharmacological adjunct to enhance efficacy of exposure-based CBT 151 [6-8]. D-cycloserine is thought to act at the glycine modulatory site of the NMDA 152 receptor. Its high affinity binding enhances synaptic plasticity, promoting emotional 153 learning processes [8] boosting therapeutic effects of CBT as a result [7, 9, 10]. 154 Experimental medicine studies have demonstrated reductions in emotional response 155 within the amygdala when paired with CBT [6], increasing activity within hippocampus 156 in a manner linked to learning [11]. In CBT for alcoholism, D-cycloserine decreased

157 cue induced brain activity across the ventral and dorsal striatum which was associated
158 with reductions in alcohol craving [12]. Clinical trials of D-cycloserine paired with CBT
159 have demonstrated reductions in symptoms of acrophobia [13], social phobia [14],
160 panic disorder [15] and obsessive compulsive disorder (OCD) over placebo [16, 17],
161 often with medium to large effect sizes.

162

Given the strong parallels between pulmonary rehabilitation and exposure-based CBT, and the strong effects of pulmonary rehabilitation on affective components of breathlessness [3, 4] we hypothesised that D-cycloserine may have therapeutic benefits in enhancing pulmonary rehabilitation.

167

168 To test this hypothesis, we performed an experimental medicine study using functional 169 magnetic resonance imaging (FMRI) markers of drug efficacy in the brain. We chose 170 this approach over a phase 3 clinical trial because the differences between COPD 171 populations and those with primary psychiatric conditions in which D-cycloserine has 172 been tested so far might necessitate a bespoke trial design. Therefore, we wanted to 173 test efficacy in the brain first. FMRI end-points are more sensitive than clinical ones 174 [18] and thus facilitate the adoption of more statistically robust approaches. This 175 means that results can be obtained with smaller sample sizes than in a phase 3 clinical 176 trial. A positive result from an FMRI study would facilitate clinical trial design and help 177 early decisions of go/no-go on further clinical development.

178

179 Methods and Materials

An overview of the methodology is presented here. Full details, including noncompletion and sensitivity analysis can be found within supplementary materials. The study and statistical analysis plan were pre-registered on clinicaltrials.gov (ID: NCT01985750) prior to unblinding. This is the first example of pre-registration of both study design and analysis plan in a respiratory neuroimaging study.

185

186 Sample Size

187 At the time of study inception (and to a large extent still to date), the literature regarding 188 D-cycloserine's effects on functional brain activity is very limited. Therefore, in order to 189 calculate the sample sizes required for this study we first took into account the 190 described effects of D-cycloserine in clinical studies of augmentation for cognitive 191 behavioural therapy for anxiety disorders, where effect sizes of up to 1.06 have been 192 reported (although more commonly 0.4 to 0.7) [13, 14, 19]. The most relevant paper 193 (on treatment of snake phobia [10]) demonstrated that effects observed with 194 neuroimaging were more sensitive than behavioural effects, therefore powering for a 195 behavioural outcome measure (breathlessness-anxiety) provided a safe margin and 196 was likely to be sufficiently conservative to detect our measures of interest. This was 197 particularly the case as compared to the relatively blunt nature of behavioural data 198 collection, functional neuroimaging carries considerably more specificity and statistical 199 power. The study was not therefore specifically powered to investigate the clinical 200 effects of D-cycloserine. In our previous study we observed an 11% (SD15%) 201 improvement in breathlessness-related anxiety, measured with our FMRI word task 202 (pre-treatment mean score 38%, post treatment mean score 27%, difference 11%, SD 203 of difference 15%) [4]. Making a conservative assumption, we estimated that D-204 cycloserine augments this response with an effect size of 0.4. Assuming a similar 205 coefficient of variation we anticipated an 18% (SD24%) improvement in 206 breathlessness-anxiety (i.e. pre-treatment mean score 38%, post treatment mean

score 20%, difference 18%, SD of difference 24%). Assuming α=0.05 and power 0.80,
then we estimated a sample size of 36 in each group randomised 1:1. As this is a
behavioural outcome, we expected this to have sufficient power to detect change in
BOLD signalling.

211

212 Participants

213 91 participants (30 female, median age 70 years; range 46-85 years) with COPD were 214 recruited immediately prior to their enrolment in a National Health Service-prescribed 215 course of pulmonary rehabilitation (full demographic information including non-216 continuation is shown in Supplementary material Table 1). From this population, 72 217 participants completed all study visits (18 female, median age 71 years (46-85 years)) 218 (Table 1 and Figure 2). Written informed consent was obtained from all participants 219 prior to the start of the study. Study approval was granted by South Central Oxford 220 REC B (Ref: 118784, Ethics number: 12/SC/0713). Study inclusion criteria were: a 221 diagnosis of COPD and admittance to pulmonary rehabilitation. Exclusion criteria 222 were: inadequate understanding of verbal and written English, significant cardiac, 223 psychiatric (including depression under tertiary care) or metabolic disease (including 224 insulin-controlled diabetes), stroke, contraindications to either D-cycloserine (including 225 alcoholism) or magnetic resonance imaging (MRI), epilepsy, claustrophobia, regular 226 therapy with opioid analgesics or home oxygen therapy.

227

228 Study drug

Participants were randomised in a double-blinded procedure to receive either 250mg oral D-cycloserine or a matched placebo, administered by the study nurse 30 minutes prior to the onset of their first four pulmonary rehabilitation sessions. 250mg dosage has been shown to be efficacious [6, 11]. D-cycloserine exerts its best effects when given immediately before exposure based therapy and only for a limited number of times [20] with daily administration associated with tachyphylaxis [13]. Therefore, the

dose timing of D-cycloserine was deliberately selected to be the first four sessions, where the greatest potential for emotional learning occurs as patients become habituated to pulmonary rehabilitation. Study participants, investigators and those performing the analysis were blinded to the treatment allocation. Both D-cycloserine and placebo were over-encapsulated to appear identical.

The following minimization criteria were used for randomisation a) centre at which pulmonary rehabilitation was performed, MRC breathlessness grade, presence of diabetes, whether the participant was taking antidepressants, the age at which the participant completed full time education and previous pulmonary rehabilitation. Full details of randomisation can be found within the supplementary materials.

245

246 Study visit protocol

Following telephone screening, participants were invited to attend their first research session (baseline) prior to starting pulmonary rehabilitation. A second study visit took place following the fourth pulmonary rehabilitation session but before the sixth session. Participants completed the remainder of their pulmonary rehabilitation course before attending a third study session (Figure 2) that occurred as close to the termination of pulmonary rehabilitation as possible and always within two weeks.

253

254 **Pulmonary Rehabilitation**

Pulmonary rehabilitation courses were run by either Oxford Health NHS Foundation
Trust, West Berkshire NHS Foundation Trust, or Milton Keynes University Hospitals
NHS Trust.

258

259 Self-report questionnaires:

Building on our previous work [4, 21] we selected a set of questionnaires with proven sensitivity to changes across pulmonary rehabilitation [4], which were designed to probe the experience of living with COPD. These were scored according to their

respective manuals: Dyspnoea-12 (D12) Questionnaire [22], Centre for Epidemiologic
Studies Depression Scale (CES-D) [23], Trait Anxiety Inventory (TRAIT) [24], Fatigue
Severity Scale [25], St George's Respiratory Questionnaire (SGRQ) [26], Medical
Research Council (MRC) breathlessness scale [27], Mobility Inventory (MI) [28],
Breathlessness catastrophising scale, adapted from the Catastrophic Thinking Scale
in Asthma [29], Breathlessness vigilance, adapted from the Pain Awareness and
Vigilance Scale [30].

270

271 *Physiological measures:*

272 Spirometry and two Modified Shuttle Walk Tests (MSWT) were collected using 273 standard protocols [31, 32]. Participant height and weight were recorded at each visit. 274 Oxygen saturations and heart rate were measured with pulse oximetry and were 275 collected at rest and following the MSWT.

276

277 MRI measures

Image acquisition: Magnetic resonance imaging of the brain was carried out using a
Siemens 3T MAGNETOM Trio. A T1-weighted (MPRAGE) structural scan (voxel size:
1 x 1 x 1 mm) was collected and used for registration purposes. A T2*-weighted,
gradient echo planar image (EPI) scan sequence (voxel size: 3 x 3 x 3 mm), TR,
3000ms; TE 30ms was used to collect FMRI data.

283

Word cue task: To probe the neural responses of breathlessness-related expectations we examined the activity of brain regions responding to breathlessness-related word cues [4, 21, 33]. This paradigm has previously been shown to be sensitive to improvements in breathlessness over a course of pulmonary rehabilitation. Brain activity was correlated with corresponding visual analogue ratings of breathlessness and breathlessness-anxiety collected during scanning. [4]. During FMRI scanning, participants were presented with a word cue, e.g., "climbing stairs" in white text on a

black background for 7 seconds. Participants were then asked, "how breathless would this make you feel" (wB) and "how anxious would this make you feel" (wA). To each question participants responded within a 7 second window using a button box and visual analogue scale (VAS). The response marker always initially appeared at the centre of the scale, with the anchors "Not at all" and "Very much" at either end. Scan duration was 7 minutes and 33 seconds.

297

298 Control task: A validated task of emotional faces was used as a control to separate 299 generalized anxiety from breathlessness specific anxiety. Fearful or happy faces were 300 presented on a black background was used to examine whether any differences in 301 brain activity patterns between D-cycloserine and placebo groups was specific to 302 breathlessness processing. Each face was shown for 500ms in blocks of 30 seconds. 303 A fixation cross was interspersed for 30 seconds between the blocks of faces. 304 Participants were instructed to respond via a button box to indicate facial gender. 305 Reaction time and accuracy were recorded throughout the task. Scan duration was 5 306 minutes and 42 sections.

307

308 Outcomes

309 Our primary outcomes focused on brain activity changes within five key regions of 310 interest, identified in previous studies of breathlessness [4, 34]. The regions of the 311 anterior insular cortex, posterior insular cortex, anterior cingulate cortex, amygdala and 312 hippocampus have all been linked to body and symptom perception as well as 313 emotional salience [35, 36]. Focusing on a small number of regions of interest is more 314 statistically powerful and therefore more likely to detect a hypothesised difference. Secondary hypotheses examined the effect of D-cycloserine across a wider region of 315 316 interest containing fifteen pre-defined brain areas. The fifteen brain areas 317 encompassed regions associated with sensory and affective processing of 318 breathlessness as well as body and symptom perception. regions.

polpotal	
It is made available under a CC-E	Y 4.0 International license .

319	
320	
321	Analysis
322	A summary of analyses is outlined here. Full details, including procedures for dealing
323	with missing data and sensitivity analysis can be found within the supplementary
324	materials. Our analysis was pre-registered and made publicly available prior to
325	unblinding
326	https://mfr.osf.io/render?url=https://osf.io/wqyf4/?action=download%26mode=render.
327	
328	Brain imaging analysis
329	Image processing was carried out using the Oxford Centre for Functional Magnetic
330	Resonance Imaging of Brain Software Library (FMRIB, Oxford, UK; FSL version 5.0.8;
331	https://ww.fmrib.ox.ac.uk/fsl/), MATLAB R2018b (Mathworks, Natick, MA), R-studio, R
332	version 3.6.1 (2019-07-05). and associated custom scripts. Functional MRI processing
333	was performed using FEAT (FMRI Expert Analysis Tool, within the FSL package).
334	
335	Data were pre-processed according to standard protocols before being entered into
336	single subject general linear models. These models captured brain activity during the
337	periods in which the breathlessness-related word cues were presented allowing us to
338	examine expectation-related processes.
339	
340	Group level analysis
341	For each patient, the following metrics were extracted from each of the five regions of
342	interest: anterior insula cortex, posterior insula cortex, anterior cingulate cortex,
343	amygdala and hippocampus, at visits one, two and three:
344	1. Mean brain activity in response to breathlessness word-cue presentation
345	2. Mean brain activity for control task of emotional faces

To test for a drug effect across each metric, the values from visit two were entered into independent linear mixed effects models where they were adjusted for age, gender and scores at visit one. To correct for multiple comparisons across regions, permutation testing (with Family Wise Error Rate (FWE) 5%) was carried out. This process was repeated separately for data collected at visit three. Models were programmed using the Ime4 function and permuco package within R version 3.6.1 (2019-07-05).

354

355 To test for a drug effect across the larger region of interest (panel B of Supplementary

Figure 1), the following voxel-wise information was collected from within the region of interest at visits one, two and three:

1. Voxel-wise brain activity in response to breathlessness word-cues presentation

359 2. Voxel-wise brain activity in response the control task of emotional faces

360

Each of the values from visit two were entered into independent general linear model (GLM), controlling for age, gender and scores at visit one. Permutation testing was performed with threshold free cluster enhancement (TFCE) (a non-parametric test) [37] using FSL's Randomise tool [38] at family wise error corrected p<0.05. The process was then repeated separately for data collected at visit three.

366

367

369 **Results**

370

371 Of the 91 participants recruited (Figure 1), 72 participants completed all three study 372 visits. Reasons for drop-out or exclusion included illness, scanner error and issues 373 with data quality. One further participant was excluded due to an error in task-data 374 collection. 71 participants were therefore assessed for study objectives. Sensitivity 375 analysis was performed and is reported within supplementary materials.

376

377 Primary outcomes

There was no significant overall effect of D-cycloserine on mean brain activity within the five key regions of interest of anterior cingulate, anterior insula cortex, amygdala, hippocampus or posterior insula cortex (family wise error rate corrected, p>0.05) at visit two or visit three (Table 2).

382

383 Secondary outcomes

There was no significant overall effect of D-cycloserine across the broader mask of fifteen regions measured voxel-wise (family wise error rate correct, p>0.05) at visit two or visit three.

387

388 No significant differences in the questionnaire measures or physiology scores were 389 found between the D-cycloserine and placebo groups at any point during the study. 390 No differences were observed between the two groups either in breathlessness ratings 391 (wB) or breathlessness related anxiety (wA) at visit two (both p=0.15 family wise error 392 rate corrected) (Table 3) or visit three (both p=0.053 family wise error rate corrected) 393 (Table 4). No significant effect of drug group was identified, using repeat measured 394 ANOVA's, for the emotional faces control task (collected during FMRI scanning) at visit 395 two (F(1,68) = 0.17, p=0.68) or visit three (F(1,68) = 0.001, p=0.97). Furthermore, no 396 significant interaction between drug group and emotional valence (happy or fearful

- faces) was identified at visit two (F(1,68) = 0.36, p=0.55) (Table 4) or visit three (F(1,68))
- = 0.002, p=0.97) (Table 5). Raw scores are reported in Supplementary Table 4.

399

- 400 Overall changes in self-report questionnaires over the course of pulmonary
- 401 rehabilitation were as expected and are presented in Supplementary Table 5.

402

403

404

406 **Discussion**

407

408 Key Findings

409 We found that 250mg of D-cycloserine administered prior to the first four sessions of 410 pulmonary rehabilitation showed no effect on breathlessness related brain activity in 411 the 5 regions of interest tested: amygdala, anterior insula, posterior insula, anterior 412 cingulate cortex or hippocampus when assessed either during (after 4-5 sessions) or 413 after the course. Likewise, there was no effect on the secondary endpoints of voxel-414 wise activity across a wider selection of brain regions. These findings suggest that D-415 cycloserine does not have the potential to move to phase 3 clinical trials in pulmonary 416 rehabilitation and that alternative drug candidates should be considered.

417

418 This is the first study to test a neuro-pharmacological adjunct to pulmonary 419 rehabilitation. A key strength of this study, in addition to its sample size, which is large 420 for a neuroimaging study of breathlessness, is its use of robust clinical trial 421 methodology which was monitored in accordance with GCP standards. We included a 422 formal sample size calculation powered for validated end points relevant to the patient 423 population, pre-registered the study design and published a statistical analysis plan 424 ahead of unblinding. Additionally, our hypotheses focused on five a-priori defined brain 425 regions with demonstrated evidence of strong modulation by D-cycloserine [9, 39] or 426 links to body, symptom perception as well as emotional salience [35, 36]. Together 427 these steps, which are rarely carried out for neuroimaging studies, ensured rigorous 428 methodology, robust findings and provide the best chance to detect an effect if present. 429

- 430 431 Why was no drug effect observed?
- 432

433 D-cycloserine may not have sufficient glutamatergic activity: While D-cycloserine 434 has not shown sufficient promise to be progressed to full-scale clinical trials, other 435 drugs may now be more attractive candidates. Paired with cognitive therapies as treatment for treatment resistant depression, ketamine and its derivative Esketamine, 436 437 which blocks pre-synaptic NMDA receptor signalling, increasing glutamate and thereby 438 synaptic plasticity, has been linked with reductions in fear and anxiety, and rapid relief 439 from symptoms [40].

440

441 Individual differences: Recent literature has highlighted the importance of individual 442 differences in response to D-cycloserine. New evidence suggests that D-cycloserine 443 has the potential to reinforce either positive or negative experiences during exposure 444 based CBT [17]. Direction of action appears to depend on stress levels, which at the 445 neurochemical level influence neurotransmitter concentrations surrounding the 446 NMDA-receptors [41]. These opposing effects may render brain activity differences 447 unobservable in a simple contrast of means. An excellent example can be observed 448 from a reanalysis of two trials which initially found no-overall effect of D-cycloserine. 449 Yet, when post exposure sessional fear was accounted for, the D-cycloserine group 450 evidenced significantly greater clinical improvement than the placebo group. However, 451 this was only the case if fear was reduced. Where fear was high at the end of a session, 452 the D-cycloserine group actually exhibited less clinical improvement than the placebo 453 group [42].

454

455 Ceiling effect: The action of D-cycloserine is known to be curtailed near the 456 therapeutic ceiling [43], and pulmonary rehabilitation is a highly effective treatment [2], 457 this may leave insufficient scope for improvement in some individuals. There is some

evidence to suggest that D-cycloserine speeds up therapeutic effects, even after a single session CBT [6]. To account for the high efficacy of pulmonary rehabilitation, and the potential for D-cycloserine to speed up learning, we also analysed brain activity after the first four rehabilitation sessions. Even at this earlier time point we found no effect of D-cycloserine. This result is in line with Rosenfield et al, who in their metaanalysis, discounted number of treatment sessions from their models after it was found to be non-significant [16].

465

466 Little evidence of D-cycloserine in older adults: Mechanisms of drug effect may 467 occur via mediated activity within hippocampus, amygdala and insula, regions which 468 overlap with brain networks of internal bodily sensation (interoception) and reappraisal 469 [6, 9, 10]. Given that our previous work, which examined changes in brain activity over 470 a course of pulmonary rehabilitation, identified decreased brain activity within insula 471 correlating with improvements to breathlessness [4], we hypothesised D-cycloserine 472 would work on this body and reappraisal network. However, older adults are not well 473 represented within the evidence base regarding D-cycloserine's action. Given the well-474 established changes to NMDA receptor function as the brain ages, D-cycloserine may 475 act differently in this population [44].

476

477 Alternative brain pathways may be more relevant. Glucocorticoids such as cortisol, 478 combined with exposure-based CBT, have shown promise in reduction of fear in phobias and post-traumatic stress disorder [7] via their action on glucocorticoid 479 480 receptors along the hypothalamic-pituitary-adrenal (HPA) axis. The exact mechanisms 481 underlying these effects is not yet fully understood, however current evidence points 482 towards either interference with retrieving fearful memories, or enhanced consolidation 483 of the new advantageous memories acquired during extinction [45]. Findings regarding 484 selective serotonin uptake inhibitors (SSRIs) meanwhile are mixed. Paired with CBT, 485 Paroxetine was found to reduce panic attacks by 50% compared to placebo [46].

However, a review of wider SSRI literature found that chronic and sub-chronic
administration was associated with reduced CBT response, leading to questions as to
whether SSRI's may even interfere with CBT effectiveness [45]

Collectively these candidate drugs boost synaptic plasticity, although via different neurochemical pathways, which may facilitate the re-setting of fearful associations within the brain. These could be used either during pulmonary rehabilitation, or as part of a precursor programme, helping to recruit harder to reach patients and support selfmanagement. Successful self-management has been highlighted as a key objective by the department of health [47] and often follows on from CBT-based programmes such as the talking therapies recommended by the British Lung Foundation

496

497 Dosing and dose timing. Questions do still remain regarding D-cycloserine's 498 optimum dosage, dose timing and number of administered sessions [16]. One recent 499 literature review suggests that up to nine doses, delivered 60-minutes before exposure 500 may yield the best results and increase effect size by up to 50% [16]. Based on the 501 available literature at the time [6, 8] and practical considerations regarding drug 502 availability, we selected a dose of 250mg for this study, administered at the first four 503 rehabilitation sessions. However, given that our maximum effect size was 0.18 (Figure 504 3), even a 50% increase would be below the commonly reported effect sizes of 0.4-505 0.7, and up to 1.06 [10, 13, 14, 19]. This strongly suggests that dose and dose timing 506 did not drive the negative result.

507

508 Conclusions

We have shown evidence that D-cycloserine does not have an effect on breathlessness related brain activity, behavioural or physiological measures over the course of pulmonary rehabilitation. This study contributes important information regarding the (un)suitability of D-cycloserine as a candidate for phase 3 clinical trials in pulmonary rehabilitation.

- 514
- 515

516 **Acknowledgements**

- 517 The authors would like to thank Jane Francis and the radiography team at the Oxford
- 518 Centre for Magnetic Resonance Imaging; Beverly Langford, Eleanor Evans and Anja
- 519 Hayen for their assistance with data collection; Oxford, Reading and Milton Keynes
- 520 pulmonary rehabilitation teams with particular thanks to Emma Tucker and Chris
- 521 Swindale, Katy Beckford and Catherine Darby, Milan Bhattacharya and Louise Worrall
- 522 and the Oxford Respiratory Trials Unit.
- 523

525 References

527	1.	Garrod, R., et al., Predictors of success and failure in pulmonary
528		<i>rehabilitation.</i> European Respiratory Journal, 2006. 27 (4): p. 788.
529	2.	Haave, E. and M. Hyland, Different short-term and longitudinal results on
530		perceived health status for asthma and COPD patients after pulmonary
531		rehabilitation. Patients living alone have the largest improvements in
532		perceived quality of life. Chron Respir Dis, 2008. 5(2): p. 69-73.
533	3.	Carrieri-Kohlman, V., et al., Additional evidence for the affective dimension
534		of dyspnea in patients with COPD. Research in Nursing & Health, 2010.
535		33 (1): p. 4-19.
536	4.	Herigstad, M., et al., Treating breathlessness via the brain: changes in brain
537		activity over a course of pulmonary rehabilitation. Eur Respir J, 2017.
538		50 (3).
539	5.	Reinecke, A., et al., <i>Early effects of exposure-based cognitive behaviour</i>
540	01	therapy on the neural correlates of anxiety. Translational psychiatry, 2018.
541		8 (1): p. 225-225.
542	6.	Reinecke, A., et al., <i>Neurocognitive processes in d-cycloserine augmented</i>
543	0.	single-session exposure therapy for anxiety: A randomized placebo-
544		<i>controlled trial.</i> Behaviour Research and Therapy, 2020. 129 : p. 103607.
545	7.	Singewald, N., et al., <i>Pharmacology of cognitive enhancers for exposure-</i>
546	/.	based therapy of fear, anxiety and trauma-related disorders. Pharmacol
547		Ther, 2015. 149 : p. 150-90.
548	8.	Woud, M.L., et al., Investigating d-cycloserine as a potential
549	0.	pharmacological enhancer of an emotional bias learning procedure.]
550		Psychopharmacol, 2018. 32 (5): p. 569-577.
551	9.	Klass, A., et al., <i>d-Cycloserine facilitates extinction learning and enhances</i>
552		extinction-related brain activation. Neurobiol Learn Mem, 2017. 144 : p.
553		235-247.
554	10.	Nave, A.M., D.F. Tolin, and M.C. Stevens, <i>Exposure therapy, D-cycloserine,</i>
555		and functional magnetic resonance imaging in patients with snake phobia:
556		a randomized pilot study. J Clin Psychiatry, 2012. 73(9): p. 1179-86.
557	11.	Onur, O.A., et al., The N-Methyl-D-Aspartate Receptor Co-agonist D-
558		Cycloserine Facilitates Declarative Learning and Hippocampal Activity in
559		<i>Humans.</i> Biological Psychiatry, 2010. 67 (12): p. 1205-1211.
560	12.	Kiefer, F., et al., Effects of d-cycloserine on extinction of mesolimbic cue
561		reactivity in alcoholism: a randomized placebo-controlled trial.
562		Psychopharmacology, 2015. 232 (13): p. 2353-2362.
563	13.	Ressler, K.J., et al., Cognitive enhancers as adjuncts to psychotherapy: use of
564		D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen
565		Psychiatry, 2004. 61 (11): p. 1136-44.
566	14.	Hofmann, S.G., et al., Augmentation of exposure therapy with D-cycloserine
567		for social anxiety disorder. Arch Gen Psychiatry, 2006. 63(3): p. 298-304.
568	15.	Otto, M.W., et al., Efficacy of d-cycloserine for enhancing response to
569		cognitive-behavior therapy for panic disorder. Biol Psychiatry, 2010.
570		67 (4): p. 365-70.
571	16.	Rosenfield, D., et al., <i>Changes in Dosing and Dose Timing of D-Cycloserine</i>
572	-	Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy

	ootuny.
It is made available under a	CC-BY 4.0 International license

573		for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.
574		J Anxiety Disord, 2019. 68 : p. 102149.
575	17.	Hofmann, S.G., D-cycloserine for treating anxiety disorders: making good
576		exposures better and bad exposures worse. Depress Anxiety, 2014. 31 (3):
577		p. 175-7.
578	18.	Burggren, A. and J. Brown, Imaging markers of structural and functional
579		brain changes that precede cognitive symptoms in risk for Alzheimer's
580		<i>disease.</i> Brain imaging and behavior, 2014. 8 (2): p. 251-261.
581	19.	Guastella, A.J., et al., A randomized controlled trial of D-cycloserine
582		enhancement of exposure therapy for social anxiety disorder. Biol
583		Psychiatry, 2008. 63 (6): p. 544-9.
584	20.	Norberg, M.M., J.H. Krystal, and D.F. Tolin, A meta-analysis of D-cycloserine
585		and the facilitation of fear extinction and exposure therapy. Biol Psychiatry,
586		2008. 63 (12): p. 1118-26.
587	21.	Herigstad, M., et al., Dyspnea-related cues engage the prefrontal cortex:
588		evidence from functional brain imaging in COPD. Chest, 2015. 148 (4): p.
589		953-961.
590	22.	Yorke, J., et al., <i>Quantification of dyspnoea using descriptors: development</i>
591		and initial testing of the Dyspnoea-12. 2010. 65 (1): p. 21-26.
592	23.	Radloff, L.S., The CES-D Scale: A Self-Report Depression Scale for Research in
593		the General Population. 1977. 1(3): p. 385-401.
594	24.	Spielberger, C.D., State-Trait Anxiety Inventory, in The Corsini Encyclopedia
595		of Psychology. 2010.
596	25.	Krupp, L.B., et al., The fatigue severity scale: Application to patients with
597		multiple sclerosis and systemic lupus erythematosus. Archives of
598		Neurology, 1989. 46 (10): p. 1121-1123.
599	26.	Jones, P.W., et al., A self-complete measure of health status for chronic
600		airflow limitation. The St. George's Respiratory Questionnaire. Am Rev
601		Respir Dis, 1992. 145 (6): p. 1321-7.
602	27.	Bestall, J.C., et al., Usefulness of the Medical Research Council (MRC)
603		dyspnoea scale as a measure of disability in patients with chronic
604		obstructive pulmonary disease. Thorax, 1999. 54 (7): p. 581-586.
605	28.	Chambless, D.L., et al., The Mobility Inventory for Agoraphobia. Behav Res
606		Ther, 1985. 23 (1): p. 35-44.
607	29.	De Peuter, S., et al., Illness-specific catastrophic thinking and
608	_ / ·	overperception in asthma. Health Psychol, 2008. 27 (1): p. 93-9.
609	30.	McCracken, L.M., K.E. Vowles, and C. Eccleston, <i>Acceptance-based</i>
610	001	treatment for persons with complex, long standing chronic pain: a
611		preliminary analysis of treatment outcome in comparison to a waiting
612		<i>phase.</i> Behav Res Ther, 2005. 43 (10): p. 1335-46.
613	31.	Bradley, J., et al., Validity of a modified shuttle test in adult cystic fibrosis.
614	51.	Thorax, 1999. 54 (5): p. 437-9.
615	32.	Levy, M.L., et al., <i>Diagnostic spirometry in primary care: Proposed</i>
616	52.	standards for general practice compliant with American Thoracic Society
617		and European Respiratory Society recommendations: a General Practice
618		Airways Group (GPIAG)1 document, in association with the Association for
619		Respiratory Technology & Physiology (ARTP)2 and Education for Health3 1
620		<u>www.gpiag.org</u> 2 <u>www.artp.org</u> 3 <u>www.educationforhealth.org.uk</u> . Prim
620 621		Care Respir J, 2009. 18 (3): p. 130-47.
021		

 2016. 223: p. 37-42. 34. Esser, R.W., et al., Brain Activation during Perception and Anticipation of Dyspnea in Chronic Obstructive Pulmonary Disease. Frontiers in physiology, 2017. 8: p. 617-617. 35. Craig, A.D., How do you feelnow? The anterior insula and human awareness. Nat Rev Neurosci, 2009. 10(1): p. 59-70. 36. Faull, O.K., A. Hayen, and K.T.S. Pattinson, Breathlessness and the body: Neuroimaging clues for the inferential leap. Cortex; a journal devoted to the study of the nervous system and behavior, 2017. 95: p. 211-221. 37. Nichols, T.E. and A.P. Holmes, Nonparametric permutation tests for functional neuroimaging: A primer with examples. Human Brain Mapping, 2002. 15(1): p. 1-25. 38. Winkler, A.M., et al., Permutation inference for the general linear model. 	622 623	33.	Herigstad, M., et al., <i>Development of a dyspnoea word cue set for studies of emotional processing in COPD.</i> Respiratory physiology & neurobiology,
 625 34. Esser, R.W., et al., Brain Activation during Perception and Anticipation of Dyspnea in Chronic Obstructive Pulmonary Disease. Frontiers in physiology, 2017. 8: p. 617-617. 628 35. Craig, A.D., How do you feelnow? The anterior insula and human awareness. Nat Rev Neurosci, 2009. 10(1): p. 59-70. 630 36. Faull, O.K., A. Hayen, and K.T.S. Pattinson, Breathlessness and the body: Neuroimaging clues for the inferential leap. Cortex; a journal devoted to the study of the nervous system and behavior, 2017. 95: p. 211-221. 633 37. Nichols, T.E. and A.P. Holmes, Nonparametric permutation tests for functional neuroimaging: A primer with examples. Human Brain Mapping, 2002. 15(1): p. 1-25. 636 38. Winkler, A.M., et al., Permutation inference for the general linear model. 			
 <i>Dyspnea in Chronic Obstructive Pulmonary Disease.</i> Frontiers in physiology, 2017. 8: p. 617-617. Craig, A.D., <i>How do you feelnow? The anterior insula and human</i> <i>awareness.</i> Nat Rev Neurosci, 2009. 10(1): p. 59-70. Faull, O.K., A. Hayen, and K.T.S. Pattinson, <i>Breathlessness and the body:</i> <i>Neuroimaging clues for the inferential leap.</i> Cortex; a journal devoted to the study of the nervous system and behavior, 2017. 95: p. 211-221. Nichols, T.E. and A.P. Holmes, <i>Nonparametric permutation tests for</i> <i>functional neuroimaging: A primer with examples.</i> Human Brain Mapping, 2002. 15(1): p. 1-25. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i> 		34	
 627 physiology, 2017. 8: p. 617-617. 628 35. Craig, A.D., <i>How do you feelnow? The anterior insula and human</i> 629 <i>awareness.</i> Nat Rev Neurosci, 2009. 10(1): p. 59-70. 630 36. Faull, O.K., A. Hayen, and K.T.S. Pattinson, <i>Breathlessness and the body:</i> 631 <i>Neuroimaging clues for the inferential leap.</i> Cortex; a journal devoted to 632 the study of the nervous system and behavior, 2017. 95: p. 211-221. 633 37. Nichols, T.E. and A.P. Holmes, <i>Nonparametric permutation tests for</i> 634 <i>functional neuroimaging: A primer with examples.</i> Human Brain Mapping, 635 2002. 15(1): p. 1-25. 636 38. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i> 		51.	
 628 35. Craig, A.D., <i>How do you feelnow? The anterior insula and human</i> 629 <i>awareness.</i> Nat Rev Neurosci, 2009. 10(1): p. 59-70. 630 36. Faull, O.K., A. Hayen, and K.T.S. Pattinson, <i>Breathlessness and the body:</i> 631 <i>Neuroimaging clues for the inferential leap.</i> Cortex; a journal devoted to 632 the study of the nervous system and behavior, 2017. 95: p. 211-221. 633 37. Nichols, T.E. and A.P. Holmes, <i>Nonparametric permutation tests for</i> 634 <i>functional neuroimaging: A primer with examples.</i> Human Brain Mapping, 635 2002. 15(1): p. 1-25. 636 38. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i> 			
 <i>awareness.</i> Nat Rev Neurosci, 2009. 10(1): p. 59-70. 36. Faull, O.K., A. Hayen, and K.T.S. Pattinson, <i>Breathlessness and the body:</i> <i>Neuroimaging clues for the inferential leap.</i> Cortex; a journal devoted to the study of the nervous system and behavior, 2017. 95: p. 211-221. 37. Nichols, T.E. and A.P. Holmes, <i>Nonparametric permutation tests for</i> <i>functional neuroimaging: A primer with examples.</i> Human Brain Mapping, 2002. 15(1): p. 1-25. 38. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i> 		35	
 630 36. Faull, O.K., A. Hayen, and K.T.S. Pattinson, <i>Breathlessness and the body:</i> 631 <i>Neuroimaging clues for the inferential leap.</i> Cortex; a journal devoted to 632 the study of the nervous system and behavior, 2017. 95: p. 211-221. 633 37. Nichols, T.E. and A.P. Holmes, <i>Nonparametric permutation tests for</i> 634 <i>functional neuroimaging: A primer with examples.</i> Human Brain Mapping, 635 2002. 15(1): p. 1-25. 636 38. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i> 		55.	
 <i>Neuroimaging clues for the inferential leap.</i> Cortex; a journal devoted to the study of the nervous system and behavior, 2017. 95: p. 211-221. 37. Nichols, T.E. and A.P. Holmes, <i>Nonparametric permutation tests for</i> <i>functional neuroimaging: A primer with examples.</i> Human Brain Mapping, 2002. 15(1): p. 1-25. 38. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i> 		26	
 the study of the nervous system and behavior, 2017. 95: p. 211-221. 37. Nichols, T.E. and A.P. Holmes, <i>Nonparametric permutation tests for</i> <i>functional neuroimaging: A primer with examples.</i> Human Brain Mapping, 2002. 15(1): p. 1-25. 38. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i> 		50.	
 633 37. Nichols, T.E. and A.P. Holmes, Nonparametric permutation tests for 634 functional neuroimaging: A primer with examples. Human Brain Mapping, 635 2002. 15(1): p. 1-25. 636 38. Winkler, A.M., et al., Permutation inference for the general linear model. 			
 634 <i>functional neuroimaging: A primer with examples.</i> Human Brain Mapping, 635 2002. 15(1): p. 1-25. 636 38. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i> 		27	
6352002. 15(1): p. 1-25.63638.Winkler, A.M., et al., Permutation inference for the general linear model.		37.	• • • •
636 38. Winkler, A.M., et al., <i>Permutation inference for the general linear model.</i>			
		00	
		38.	
637 Neuroimage, 2014. 92 : p. 381-97.			
638 39. Thompson, L.T., J.R. Moskal, and J.F. Disterhoft, <i>Hippocampus-dependent</i>		39.	
639 <i>learning facilitated by a monoclonal antibody or D-cycloserine.</i> Nature,			
640 1992. 359 (6396): p. 638-641.			
641 40. Ziffra, M., Panic disorder: A review of treatment options. Ann Clin		40.	
642 Psychiatry, 2021. 33 : p. 124-33.			
643 41. Schade, S. and W. Paulus, <i>D-Cycloserine in Neuropsychiatric Diseases: A</i>		41.	
644 <i>Systematic Review.</i> The international journal of			Systematic Review. The international journal of
645 neuropsychopharmacology, 2016. 19 (4): p. pyv102.	645		neuropsychopharmacology, 2016. 19 (4): p. pyv102.
646 42. Smits, J.A.J., et al., <i>D-cycloserine enhancement of exposure therapy for social</i>	646	42.	Smits, J.A.J., et al., <i>D-cycloserine enhancement of exposure therapy for social</i>
647 <i>anxiety disorder depends on the success of exposure sessions.</i> Journal of	647		anxiety disorder depends on the success of exposure sessions. Journal of
648 psychiatric research, 2013. 47 (10): p. 1455-1461.	648		psychiatric research, 2013. 47 (10): p. 1455-1461.
649 43. Choi, D.C., et al., <i>Pharmacological Enhancement of Behavioral Therapy:</i>	649	43.	Choi, D.C., et al., <i>Pharmacological Enhancement of Behavioral Therapy:</i>
650 Focus on Posttraumatic Stress Disorder, in Behavioral Neurobiology of	650		Focus on Posttraumatic Stress Disorder, in Behavioral Neurobiology of
651 <i>Anxiety and Its Treatment</i> , M.B. Stein and T. Steckler, Editors. 2010,	651		
652 Springer Berlin Heidelberg: Berlin, Heidelberg. p. 279-299.	652		
653 44. Kumar, A. and T.C. Foster, Alteration in NMDA Receptor Mediated	653	44.	
654 <i>Glutamatergic Neurotransmission in the Hippocampus During Senescence.</i>			
655 Neurochemical Research, 2019. 44 (1): p. 38-48.			
656 45. Reinecke, A. and C.J. Harmer, A Cognitive-Neuropsychological Account of		45.	
657 Treatment Action in Anxiety: Can We Augment Clinical Efficacy?			
658 Psychopathology Review, 2016. a3 (1): p. 77-109.			
659 46. Oehrberg, S., et al., <i>Paroxetine in the Treatment of Panic Disorder a</i>		46.	
660 <i>Randomised, Double-Blind, Placebo-Controlled Study.</i> British Journal of		101	
661 Psychiatry, 1995. 167 (3): p. 374-379.			
662 47. Health, D.o., An Outcomes Strategy for Chronic Obstructive Pulmonary		47	
663 Disease (COPD) and Asthma. 2011.		171	
664			





Figure 2. A schematic demonstrating order of visits, rehabilitation sessions and tablet administration throughout the study period. Participants took part in one study visit prior to their first pulmonary rehabilitation session. Study drug/placebo were administered on four occasions over the first four rehabilitation sessions. A second study visit occurred after the final drug/placebo administration. Participants continued with their pulmonary rehabilitation course for a further four weeks before returning for a third study visit.






medRxiv preprint doi? https://doi.org/10.1101/2021.06.24.21259306; this version posted November 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in



709 Figure 3. Effect sizes and confidence intervals for each of the five regions of interest at visits 710

two and three for D-cycloserine and Placebo groups.





713 **TABLES**

714

- 715 Table 1. Demographic information from the 72 participants who completed all three study visits.
- 716 Variance is expression either in terms of standard deviation (SD) or interguartile range (IQR)
- 717 depending on the normality of the underlying data distribution. BMI = Body Mass Index, MRC
- 718 = Medical Research Council. SpO₂% = Peripheral Oxygen saturation, expressed as a
- 719 percentage. FEV = Forced Expiratory Volume. FVC = Forced Vital Capacity. Also listed with
- 720 prevalence in brackets are recorded comorbidities ordered by frequency

	١	/isit 1
	(Pre-rehabilitation)	
	D-cycloserine	Placebo
Age (median years / range)	71.0 / (47-81)	71.5 / (46-85)
Smoking pack-years (years / IQR)	34.0 / (25.6)	30.0 / (30.0)
Duration of breathlessness (years / IQR)	8.0 (17.0)	9.5 (10.0)
Total exacerbations (number / IQR)	0.0 (1.0)	1.0 (2.3)
BMI (kg.m-2 ± SD)	27.3 ± 6.5	26.9 ± 5.7
MRC breathlessness scale (IQR)	3.0 (1)	2.5 (1)
Resting SpO ₂ % (IQR)	95 / (3.3)	95 / (3.0)
Resting heart rate (beats.min-1 ± SD)	80.8 ± 13.4	80.8 ± 14.9
FEV1/FVC (IQR)	0.53 / (0.17)	0.56 / (0.13)

Comorbidities (frequency)

Asthma (14)	Asthma (11)
Hypertension (13)	Hypertension (11)
Gastro-oesophageal reflux (10)	Gastro-oesophageal reflux (12)
Swelling of both ankles (11)	Swelling of both ankles (8)
Surgery to the chest (6)	Surgery to the chest (7)
Depression (6)	Depression (2)
Diabetes (3)	Diabetes (6)
Heart attack (4)	Heart attack (5)
Bronchiectasis (3)	Bronchiectasis (4)
Osteoporosis (2)	Osteoporosis (4)
Arrhythmia (3)	Arrhythmia (4)
Inflammatory bowel disease (2)	Inflammatory bowel disease (3)
Peptic ulcer (3)	Peptic ulcer (2)
Heart failure (1)	Heart failure (1)
Tuberculosis (1)	Neuromuscular weakness (2)

Table 2. Significance of overall effect of D-cycloserine on mean brain activity within the five key

- regions of interest at visits two, having accounted for scores at visit one. Significance is reported
- as Family Wise Error (p<0.05) corrected p-values of the difference

Region of interest	Estimate	Std. Error	Visit two (p-value)
Anterior cingulate cortex	0.066	0.059	0.70
Anterior insula	0.019	0.058	0.98
Amygdala	0.097	0.059	0.40
Hippocampus	0.018	0.058	0.98
Posterior insula	-0.013	0.059	0.98

Table 3. Significance of overall effect of D-cycloserine on mean brain activity within the five key

regions of interest at visits three, having accounted for scores at visit one. Significance is

reported as Family Wise Error (p<0.05) corrected p-values of the difference

Region of	interest	Estimate	Std. Error	Visit three (p-value)
Anterior cingu	late cortex	-0.009	0.056	0.98
Anterior	insula	0.019	0.055	0.98
Amygo	lala	0.055	0.056	0.78
Hippoca	mpus	0.014	0.056	0.98
Posterior	insula	0.068	0.056	0.70

738 739 740	Table 4. Scores on questionnaire, behavioural and physiological measures for drug and
,	
741	placebo group during (visit two). Measures are expressed as a "change score". Values are
742	calculated as baseline visit (visit one) minus the later visit, thus positive values indicate an
743	improvement or, in the case of the faces task, a faster reaction time (ms). Significance is
744	reported as Family Wise Error (p<0.05) corrected p-values of the difference in scores between
745	drug and placebo groups at visit two, accounting for scores at visit one. Values are either
746	recorded as mean and standard deviation (1) or as median and interquartile range (2)
747	depending on the normality of distribution. BMI = Body Mass Index, MRC = Medical Research
748	Council clinical measure of breathlessness, MSWT = Modified Shuttle Walk Test, HR = Heart
749	rate, Sats = Peripheral Oxygen saturation, expressed as a percentage

		Visit Two	
	D-cycloserine	Placebo	p-value
Catastrophising	1.0 (5.3) ²	2.0 (4.0) ²	0.84
Depression	1.2 ± 6.4 ¹	3.2 ± 5.4 ¹	0.55
D12	3.8 ± 5.4 ¹	2.2 ± 4.7 ¹	0.55
Fatigue	7.0 (12.3) ²	4.5 (12.0) ²	0.64
BMI	-0.16 (0.6) ²	0.0 (0.6) ²	0.55
MRC	0 (0.5) ²	0 (0.0) 2	0.85
MSWT Distance (m)	0.0 (111.3) ²	5.0 (70) ²	0.85
MSWT Borg Start	0 (1) ²	0 (1) ²	0.85
MSWT Borg Change	0.5 (1.5) ²	0.5 (2) ²	0.85
MSWT HR Start	-0.30 ± 13.9 ¹	1.4 ± 13.2 ¹	0.85
MSWT HR Change	-45.4 ± 23.0 ¹	-47.5 ± 25.4 ¹	0.90
MSWT Sats Start	-0.30 ± 2.2 ¹	-0.1 ± 2.2 ¹	0.85
MSWT Sats Change	0 (5) ²	0 (4.0) ²	0.91
Vigilance	3.8 ± 10.6 ¹	1.8 ± 13.6 ¹	0.85
FEV1/FVC	0 (0.1) ²	0 (0.1) ²	0.55
Avoidance – Alone	0.1 (0.4) ²	0.1 (0.2) ²	0.91
Avoidance -Accompanied	0.0 (0.3) ²	0.1 (0.2) ²	0.55
St George – Active	6.7 (10.6) ²	3.3 (12.8) ²	0.55
St George – Impact	4.3 ± 7.7 ¹	1.5 ± 8.1 ¹	0.55
St George – Symptom	4.0 ± 11.5 ¹	4.3 ± 10.7 ¹	0.92
Trait	4.0 (5.5) ²	1.0 (7.0) ²	0.55
Breathlessness Anxiety (wA)	0.4 (29.0) ²	5.0 (17.8) ²	0.15
Breathlessness Severity (wB)	-0.4 ± 21.3 ¹	9.2 ± 23.1 ¹	0.15
Fearful Faces (ms)	5.2 (116.5)	-13.5 (73.0)	
Happy Faces (ms)	12.1 (112.8)	-1.9 (106.9)	
Main effect of drug group	F(1,68) = 0.17, p=0.68		
Interaction drug group:emotion	F(1,68) = 0.36, p=0.55		

755	Table 5. Scores on questionnaire, behavioural and physiological measures for drug and
756	placebo group following pulmonary rehabilitation (visit three). Measures are expressed as a
757	"change score". Values are calculated as baseline visit (visit one) minus the later visit, thus
758	positive values indicate an improvement or, in the case of the faces task, a faster reaction time
759	(ms). Significance is reported as Family Wise Error (p<0.05) corrected p-values of the
760	difference in scores between drug and placebo groups at visit three, accounting for scores at
761	visit one. Values are either recorded as mean and standard deviation (1) or as median and
762	interquartile range (2) depending on the normality of distribution. BMI = Body Mass Index, MRC
763	= Medical Research Council clinical measure of breathlessness, MSWT = Modified Shuttle
764	Walk Test, HR = Heart rate, Sats = Peripheral Oxygen saturation, expressed as a percentage.

	Visit Three		
	D-cycloserine	Placebo	p-value
Catastrophising	3.0 (7) ²	4.5 (8) ²	0.86
Depression	3.1 ± 6.6 ¹	4.7 ± 5.3 ¹	0.86
D12	3.0 (8.3) ²	2.5 (8) ²	0.86
Fatigue	9.7 ± 12.5 ¹	5.7 ± 12.0 ¹	0.86
BMI	0.0 (0.8) ²	-0.1 (0.9) ²	0.86
MRC	0 (1) ²	0 (1) ²	0.86
MSWT Distance (m)	40 (92.5) ²	30 (70) ²	0.86
MSWT Borg Start	0 (0.5) 2	0 (1) ²	0.86
MSWT Borg Change	0.1 ± 1.9 ¹	-0.1 ± 1.6 ¹	0.86
MSWT HR Start	2.7 ± 10.4 ¹	2.4 ± 13.5 ¹	0.98
MSWT HR Change	-51 (29.3) ²	-53.5 (27) ²	0.86
MSWT Sats Start	0.0 (2) ²	0.0 (3) ²	0.86
MSWT Sats Change	-1 (7) ²	$0(3)^2$	0.86
Vigilance	5.0 (12) ²	5.5 (12) ²	0.86
Spirometry	0 (0.1) ²	0 (0.1) ²	0.86
Avoidance – Alone	0.1 (0.3) ²	0.1 (0.3) ²	0.98
Avoidance - Accompanied	0.0 (0.3) ²	0.1 (0.3) ²	0.86
St George – Active	6.0 (15.1) ²	6.2 (13.4) ²	0.86
St George – Impact	5.1 (12.7) ²	5.0 (8.6) ²	0.86
St George – Symptom	6.5 ± 12.5 ¹	6.4 ± 12.7 ¹	0.97
Trait	2.7 ± 5.8 ¹	3.3 ± 7.6 ¹	0.86
Breathlessness Anxiety (wA)	3.0 (7.0) ²	7.3 (16.8) ²	0.053
Breathlessness Severity (wB)	3.1 (15.6) ²	8.4 (13.1) ²	0.053
Fearful Faces (ms)	-0.2 (70.7)	-58.2 (88.4)	
Happy Faces (ms)	-10.5 (126.7)	-43.5 (106.4)	
Main effect of drug group	F(1,68) = 0.001, p=0.97		
Interaction drug group:emotion	F(1,68) = 0.002, p=0.97		